Sunday, May 29, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Cross-reactive coronavirus antibodies might not be cross-neutralizing

by Medical Finance
in Coronavirus
Study: Function matters: Coronavirus cross-binding antibodies do not cross-neutralize. Image Credit: Andrii Vodolazhskyi / Shutterstock
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

In a recent study posted to Research Square* preprint server, researchers reported that cross-reactive antibodies against coronaviruses (CoVs) might not cross-neutralize all CoVs.

Several studies have reported that, in binding and pseudovirus neutralization assays, exposure to CoVs or vaccination against them induces cross-reactive antibodies, including against the latest severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, plasma from the pre-coronavirus disease 2019 (COVID-19) pandemic times could not neutralize live SARS-CoV-2.

Occasionally, the results of binding assays are referred to as neutralizing, but the relevance of binding assays is different from the neutralization of viruses by antibodies. For example, recent studies have reported that antibodies against SARS-CoV-2 could bind to seasonal CoVs, and it remains unclear whether these cross-reactive antibodies could neutralize the seasonal CoVs.

Study: Function matters: Coronavirus cross-binding antibodies do not cross-neutralize. Image Credit: Andrii Vodolazhskyi / ShutterstockStudy: Function matters: Coronavirus cross-binding antibodies do not cross-neutralize. Image Credit: Andrii Vodolazhskyi / Shutterstock

About the study

In the present study, researchers evaluated whether SARS-CoV-2 infection or vaccination-induced immune responses could cross-neutralize seasonal CoVs.

Antibody concentrates were prepared from the plasma of SARS-CoV-2-naïve donors (pre-pandemic), plasma from COVID-19-recovered donors (post-COVID), or vaccinated donors (pandemic). The collected plasma specimens were used to prepare immunoglobulin (IG) lots through a licensed process, which were then tested to neutralize SARS-CoV-2 and human CoVs (HCoVs) such as OC43 and NL63. The pre-pandemic and pandemic IG were prepared from the plasma of donors in the United States (US) from April to June 2020 and July to September 2021, respectively. Post-COVID IG was obtained from donors from Austria or the US.

A previously established protocol determined neutralizing antibody (nAb) titers against SARS-CoV-2. Similarly, nAb titers against both HCoVs were evaluated. In brief, the serially diluted (IG) specimens were incubated with either HCoV at 103 median tissue culture infectious dose (TCID50) per milliliter (ml). The cytopathic effect was studied after 9 – 11 days of incubation of HCoV-NL63 on LLC-MK2 cells and 6 – 8 days of HCoV-OC43 on MRC-5 cells. The resultant 50% virus neutralization (µNT50) was estimated using the Spearman-Karber method and subsequently normalized to an internal control. The nAb potency was compared between pre-pandemic, pandemic, and post-COVID IG lots.

Neutralizing antibody titers in immunoglobulin (IG) lots manufactured from pre-pandemic plasma (N=16), plasma of post-COVID-19 individuals (post-COVID,

Neutralizing antibody titers in immunoglobulin (IG) lots manufactured from pre-pandemic plasma (N=16), plasma of post-COVID-19 individuals (post-COVID, N=21), and plasma of mostly COVID-19 vaccinated donors (pandemic, N=18) against (A) SARS-CoV-2, (B) Human Coronavirus NL63 (HCoV-NL63) and (C) HCoV-OC43. Box plots show medians with 25th to 75th percentile ± min/max as whiskers. Geometric mean titers (GMT) are indicated below the x-axis.

Findings

About 363 IG lots were characterized for nAbs against SARS-CoV-2 and HCoVs. None of the IG lots prepared from pre-pandemic donors neutralized SARS-CoV-2. The post-COVID IG exhibited a mean neutralizing activity of 1267 international units (IU) per ml, lower than the mean nAb titers (5122 IU/ml) of pandemic IG lots. In contrast, the pre-pandemic IG neutralized HCoV-OC43 (363 µNT50 geometric mean titer [GMT]) and NL63 (5652 µNT50 GMT). The neutralization of both HCoVs was comparable across the three types of IG preparations.

From September 2020 to October 2021, about 326 IG lots were prepared and screened for nAbs against SARS-CoV-2 and HCoVs. The IG preparations from September 2020 had a mean nAb titer of 2 IU/ml against SARS-CoV-2, which increased to 4210 IU/ml for IG lots prepared in October 2021. Nevertheless, the nAb titers against HCoVs remained relatively stable during this period.

Neutralization of SARS-CoV-2, HCoV-NL63, and HCoV-OC43 by immunoglobulin (IG) released September 2020 – September 2021 (N=326; 13–31 lots / month). SARS-CoV-2 neutralization was normalized to WHO International Standard 20/136 and reported as international units / milliliter (IU/ml). HCoV titers were normalized to an internal standard and reported as µNT50 titer [norm. 1:X]. Shown are geometric mean titer ± 95% confidence intervals.

Neutralization of SARS-CoV-2, HCoV-NL63, and HCoV-OC43 by immunoglobulin (IG) released September 2020 – September 2021 (N=326; 13–31 lots / month). SARS-CoV-2 neutralization was normalized to WHO International Standard 20/136 and reported as international units / milliliter (IU/ml). HCoV titers were normalized to an internal standard and reported as µNT50 titer [norm. 1:X]. Shown are geometric mean titer ± 95% confidence intervals.

Conclusions

Consistent with several other reports, the authors did not observe SARS-CoV-2 neutralization by IG preparations from plasma of pre-pandemic donors. Although post-COVID IG lots potently neutralized SARS-CoV-2, IG preparations from vaccinated donors were nearly 4-fold more potent. The pre-pandemic IG neutralized HCoVs with high potency.

In contrast, post-COVID and pandemic IG lots significantly and potently neutralized SARS-CoV-2. The neutralizing activity of post-COVID and pandemic IG against HCoVs was comparable to that of pre-pandemic IG lots.

The current study’s findings suggested that antibody binding or pseudovirus neutralization assay results might not necessarily reflect the neutralization of live viruses.

Notably, plasma from a SARS-CoV-2-infected or vaccinated donor contains both IgG and IgM, while commercial IG preparations only concentrate IgG, which might explain the observed results. The authors posit that IgM might be cross-neutralizing while IgG, despite being cross-reactive between seasonal CoVs and SARS-CoV-2, might not be cross-neutralizing.

*Important notice

Research Square publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Prediction and validation of host cleavage targets of SARS-CoV-2 3C-like protease. ​​​​​​​Image Credit: NIAID

An algorithm to predict host cleavage targets of SARS-CoV-2 3CLPro

by Medical Finance
May 28, 2022
0

In an effort to better understand how the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) selectively targets and damages specific...

Study: Severity of maternal SARS-CoV-2 infection and perinatal outcomes during the Omicron variant dominant period: UK Obstetric Surveillance System national cohort study. Image Credit: christinarosepix / Shutterstock.com

Maternal and neonatal outcomes during UK’s SARS-CoV-2 Omicron wave

by Medical Finance
May 28, 2022
0

According to the World Health Organization (WHO), coronavirus disease 2019 (COVID-19), which is caused by infection with the severe acute...

Study: Cellular and humoral immune response to a third dose of BNT162b2 COVID-19 vaccine - a prospective observational study. Image Credit: Chaay_Tee / Shutterstock.com

BNT162b2 booster vaccination induces robust humoral and cellular immune responses

by Medical Finance
May 28, 2022
0

In a recent study published on the medRxiv* preprint server, scientists evaluate the humoral and cellular immune responses in individuals...

Study: Genomic Characterisation Reveals a Dominant Lineage of SARS-CoV-2 in Papua New Guinea. Image Credit: REC Stock Footage/Shutterstock

Genomic characterization of the circulating SARS-CoV-2 lineages in Papua New Guinea

by Medical Finance
May 28, 2022
0

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of the coronavirus disease 2019 (COVID-19), has infected around 2.7...

Study: Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2. Image Credit: ktsdesign / Shutterstock

New insight into SARS-CoV-2 main protease opens door to new viral inhibitors

by Medical Finance
May 29, 2022
0

A recent study has revealed a full cycle of substrate cleavage for the main protease of the severe acute respiratory...

Study: Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA1273 Covid-19 vaccine efficacy clinical trial. Image Credit: ustas7777777 / Shutterstock.com

Impact of COVID-19 vaccination on anti-nucleocapsid antibody levels

by Medical Finance
May 28, 2022
0

A reliable method to assess infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in vaccinated individuals has yet...

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Genomic and Virological Characterization of SARS-CoV-2 Variants in a Subset of Unvaccinated and Vaccinated U.S. Military Personnel. Image Credit: Emily C. McCormick / Shutterstock.com
    Characterization of SARS-CoV-2 variants in unvaccinated and vaccinated U.S. military
  • Two cell embryo Mitosis under microscope 3D illustration Illustration Andrii Vodolazhskyi M1 4bb73c51d46c449285a21e8af28684d6 620x480
    UW Medicine scientists contribute to the publication of first complete, gapless genome sequence
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply